Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) Kits ELISA

CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions CYP2C19 Anticorps (39) et CYP2C19 Protéines (3) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
CYP2C19 1557 P33261
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top CYP2C19 Kits ELISA sur

Showing 3 out of 19 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Fournisseur Livraison Prix Détails
Rat 0.28 ng/mL 0.78-50 ng/mL 96 Tests Connectez-vous pour afficher 13 to 16 Days
Humain 0.264 ng/mL 0.62 ng/mL - 40 ng/mL 96 Tests Connectez-vous pour afficher 13 to 16 Days
Humain 0056 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests Connectez-vous pour afficher 15 to 17 Days

Plus Kits ELISA pour CYP2C19 partenaires d'interaction

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) interaction partners

  1. The adverse impact of CYP2C19*2 polymorphisms was found not only in the risk of the presence of coronary heart disease (CHD), but also in the adverse cardiovascular events in CHD patients during the follow-up period of 14 months.

  2. Polymorphism of the CYP2C19 gene may influence the effectiveness indices of Phenazepam therapy in patients with anxiety disorders comorbid with alcohol dependence.

  3. CYP2C19*2 polymorphism is not a risk factor for peptic ulcer in Polish population; the results suggested there is some interaction between gender, CYP2C19*2 polymorphism, and pathogenesis of H. pylori infection development

  4. The higher risk of major adverse cardiovascular or cerebrovascular associated with clopidogrel use in CYP2C19 LOF allele carriers suggests that use of genotype-guided DAPT in practice may improve clinical outcomes.

  5. The CYP2C19*2 allele is common in the Palestinian population and its reduced metabolic activity is associated with increased incidence of major cardiac events in patients receiving clopidogrel.

  6. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype.

  7. The effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.

  8. It was found that progesterone (P4) modulated the both kinetic and equilibrium constants of CYB5A/CYP17A1 and CYB5/CYP21A2 complex formation and complexes, while not affecting the CYB5A/CYP2C19 interaction.

  9. CYP2C19 polymorphism affects residual platelet reactivity during maintenance with prasugrel in Korean outpatients.

  10. The carriage of CYP2C19*2 or *3 mutant allele was significantly associated with attenuated platelet response to clopidogrel and increased clopidogrel resistance risk.

  11. These results highlight that CYP2C19*2, along with diabetes, and use of proton pump inhibitor and statin are important factors jointly associated with variability in clinical response to Dual antiplatelet therapy following acute coronary syndrome in Egyptians

  12. Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

  13. The CYP2C19 genotype had a substantial impact on exposure and therapeutic failure of escitalopram, as measured by switching of antidepressant therapy. The results support the potential clinical utility of CYP2C19 genotyping for individualization of escitalopram therapy.

  14. CYP2C19 genetic polymorphism may be associated with the increased risk of cerebral infarction in the elderly

  15. study characterizes two new haplotypes in Scandinavian subjects, each containing two clinically important single nucleotide polymorphisms in CYP2C19 and CYP2C8, respectively

  16. In patients with high-risk TIA or minor ischemic stroke CYP2C19 loss of function SNP was associated with increased risk of adverse cerebrovascular outcomes in patients in the lowest quintile of estimated glomerular filtration rate.

  17. carriage of CYP2C19*2 polymorphism, in diabetes mellitus patients, might be a potential predictor of persisting clopidogrel platelet reactivity in these high-risk individuals

  18. We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment.

  19. The CYP2C19 polymorphism is associated with the frequency of major adverse cardiovascular events, but is not related to the incidence of bleeding after percutaneous coronary intervention in Japanese patients receiving clopidogrel.

  20. CYP2C19 genotype-based dosing combined with therapeutic drug monitoring will support individualization of Voriconazole dosing, and potentially will minimize toxicity and maximize therapeutic efficacy

CYP2C19 profil antigène

Antigen Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C19

  • cytochrome P450 family 2 subfamily C member 19 (CYP2C19) anticorps
  • cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) anticorps
  • cytochrome P450 2C19 (CYP2C19) anticorps
  • CPCJ anticorps
  • CYP2C anticorps
  • P450C2C anticorps
  • P450IIC19 anticorps

Protein level used designations for CYP2C19

(R)-limonene 6-monooxygenase , (S)-limonene 6-monooxygenase , (S)-limonene 7-monooxygenase , CYPIIC17 , CYPIIC19 , S-mephenytoin 4-hydroxylase , cytochrome P-450 II C , cytochrome P450 2C19 , cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 , cytochrome P450-11A , cytochrome P450-254C , flavoprotein-linked monooxygenase , mephenytoin 4'-hydroxylase , mephenytoin 4-hydroxylase , microsomal monooxygenase , xenobiotic monooxygenase , cytochrome P450 2C

1557 Homo sapiens
510380 Bos taurus
100534653 Ovis aries
Fournisseurs de qualité sélectionnés pour CYP2C19 (CYP2C19) Kits ELISA
Avez-vous cherché autre chose?